Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 13, 2011
DARPins: an efficient targeting domain for lentiviral vectorsRobert C Münch, Michael D Mühlebach, Thomas Schaser, et al.
STAR Protocols|December 21, 2022
Protocol to dissociate healthy and infected murine- and hamster-derived lung tissue for single-cell transcriptome analysisPeter Pennitz, Cengiz Goekeri, Jakob Trimpert, et al.
Human Gene Therapy|August 28, 2023
Recent Advances Using Genetic Therapies Against Infectious Diseases and for VaccinationAnne Galy, Ben Berkhout, Karine Breckpot, et al.
Virology|December 22, 2015
Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challengeBenjamin Gabriel, Uwe Fiebig, Oliver Hohn, et al.
Virus Research|December 26, 2013
A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strainsSabine Heidmeier, Jan R H Hanauer, Katrin Friedrich, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaquesIris Völker, Patricia Bach, Cheick Coulibaly, et al.
NPJ Vaccines|March 25, 2023
A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9Cindy Hörner, Anna H Fiedler, Bianca S Bodmer, et al.
NPJ Vaccines|March 18, 2025
Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19Aileen Ebenig, Mona V Lange, Michelle Gellhorn Serra, et al.
Cancer Research|September 23, 2010
Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virusMichael D Mühlebach, Thomas Schaser, Martina Zimmermann, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2020
A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccineCindy Hörner, Christoph Schürmann, Arne Auste, et al.
Pageof 5